Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study
Authors' conclusion
METS-IR is an independent predictor of clinical worsening in patients with CTEPH. It offers a convenient marker for assessing disease severity and long-term outcomes in clinical risk assessment.
Study context
- Population
- Patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) between January 2013 and December 2022
- Participants
- 516 patients
- Exposure
- Insulin resistance surrogates and clinical worsening
- Outcome
- Clinical worsening
- Follow-up
- Mean 2.5 years'
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
All-cause death or worsening condition
110 participants
Metabolic score for IR (METS-IR) per 1.0-SD increment, HR (95% CI 1.06-1.53), fully adjusted
1.27
p = 0.009
Observational data: associations, not effects.
Further findings
| Outcome | Low to intermediate-low risk | High to intermediate-high risk | P value |
|---|---|---|---|
| METS-IR by risk categorySignificantly increased in high to intermediate-high risk | 36.2 ± 6.7 | 37.7 ± 8.7 | P = 0.038 |
| TyG-BMI index by risk categorySignificantly increased in high to intermediate-high risk | 204.0 ± 36.2 | 212.6 ± 46.5 | P = 0.022 |
METS-IR and disease severity markers
- METS-IR correlated with WHO functional class, 6-minute walk distance and NT-proBNP
Original publication
Association of insulin resistance surrogates with disease severity and adverse outcomes in chronic thromboembolic pulmonary hypertension: a multicenter cohort study. Cardiovasc Diabetol. Published 19 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →